Performance Review - In H1 2025, the company achieved operating revenue of 1.496 billion, a year-on-year decrease of 4.03% [1] - The net profit attributable to the parent company was 167 million, down 9.51% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 136 million, a decline of 17.98% year-on-year [1] - The company implemented strategic adjustments to low-efficiency product categories, resulting in a gross margin increase of 1.8 percentage points [1] - Revenue breakdown: Rehabilitation aids contributed 563 million (37.63%), medical care products 424 million (28.32%), and health monitoring products 271 million (18.11%) [1] Growth Potential - Certain core product categories showed strong growth momentum in H1 2025 [1] - Sales of self-developed ventilators increased significantly starting in Q2, along with good performance from blood glucose and uric acid integrated machines, pre-heating thermometers, and home testing strips [1] - Continuous product iteration and channel optimization have strengthened the market position and competitive advantage of core categories, laying a solid foundation for future revenue growth [1] Hearing Aid Business Development - The hearing aid business saw over 20% year-on-year revenue growth in H1 2025 [2] - The company plans to accelerate the implementation of its digital strategy, utilizing a new retail management system to enhance marketing strategies, product structure adjustments, and inventory turnover management [2] - As the proportion of older stores increases, the hearing aid business is expected to gradually turn profitable, potentially becoming the company's second growth curve [2] Profit Forecast - Revenue projections for 2025-2027 are 3.325 billion, 3.794 billion, and 4.316 billion, with year-on-year growth rates of 11.48%, 14.09%, and 13.77% respectively [3] - Expected net profit attributable to the parent company for the same period is 380 million, 466 million, and 548 million, with year-on-year growth rates of 21.79%, 22.63%, and 17.75% respectively [3] - Price-to-earnings ratios for 2025-2027 are projected at 22x, 18x, and 15x, with corresponding PEG ratios of 1.02, 0.80, and 0.87 [3]

Investment Rating - The investment rating for the company is "Buy" [10][15] Core Insights - The company reported a revenue of 1.496 billion yuan in H1 2025, a year-on-year decrease of 4.03%, and a net profit attributable to the parent company of 167 million yuan, down 9.51% year-on-year [4] - Strategic adjustments were made to low-efficiency product categories, resulting in a gross margin increase of 1.8 percentage points [5] - Core product categories showed strong growth momentum, with significant sales increases in self-developed respiratory machines and other key products [6] - The hearing aid business is expected to gradually turn profitable, with a revenue growth of over 20% in H1 2025, indicating the emergence of a second growth curve for the company [7] Financial Performance - Revenue projections for 2025-2027 are 3.325 billion yuan, 3.794 billion yuan, and 4.316 billion yuan, with year-on-year growth rates of 11.48%, 14.09%, and 13.77% respectively [8] - Net profit attributable to the parent company is expected to be 380 million yuan, 466 million yuan, and 548 million yuan for the same period, with growth rates of 21.79%, 22.63%, and 17.75% respectively [8] - The company’s PE ratios for 2025-2027 are projected to be 22 times, 18 times, and 15 times, with corresponding PEG ratios of 1.02, 0.80, and 0.87 [8]

湖南启元律师事务所 关于 可孚医疗科技股份有限公司 2025年第三次临时股东会的 法律意见书 二零二五年九月 1 致：可孚医疗科技股份有限公司 湖南启元律师事务所（以下简称"本所"）接受可孚医疗科技股份有限公司（以 下简称"公司"）的委托，指派本所律师出席了公司 2025 年第三次临时股东会（以 下简称"本次股东会"），对本次股东会的召集和召开程序、出席会议人员及召集 人的资格、表决程序和表决结果的合法有效性进行现场律师见证，并发表本法律 意见。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华 人民共和国证券法》（以下简称"《证券法》"）《上市公司股东会规则》（以下 简称"《股东会规则》"）等我国现行法律、法规、规范性文件以及《可孚医疗科 技股份有限公司章程》（以下简称"《公司章程》"）的有关规定出具本法律意见 书。 本所律师声明如下： （一）本所律师根据本法律意见书出具日以前已经发生或者存在的事实，严 格履行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证， 保证本法律意见所认定的事实真实、准确、完整，所发表的结论性意见合法、准 确，不存在虚假记载、误导性陈述或者重大遗漏 ...

可孚医疗科技股份有限公司 章 程 2025年9月 1 | 第一章 | 总则 | 3 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 4 | | 第三章 | 股份 | 5 | | 第一节 | 股份增减和回购 | 6 | | 第二节 | 股份转让 | 7 | | 第四章 | 股东和股东会 | 8 | | 第一节 | 股东 | 8 | | 第二节 | 控股股东和实际控制人 | 11 | | 第三节 | 股东会的一般规定 | 13 | | 第四节 | 股东会的召集 | 16 | | 第五节 | 股东会的提案与通知 | 18 | | 第六节 | 股东会的召开 | 19 | | 第七节 | 股东会的表决和决议 | 22 | | 第五章 | 董事和董事会 | 26 | | 第一节 | 董事 | 26 | | 第二节 | 董事会 | 30 | | 第三节 | 独立董事 | 34 | | 第四节 | 董事会专门委员会 | 37 | | 第六章 | 总裁及其他高级管理人员 | 38 | | 第七章 | 财务会计制度、利润分配和审计 40 | | | 第一节 | 财务会计制度 | 40 | | 第二 ...

证券代码：301087 证券简称：可孚医疗 公告编号：2025-069 可孚医疗科技股份有限公司 2025年第三次临时股东会决议公告 3、会议召开方式：采取现场投票与网络投票相结合的方式 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、会议召开时间： （1）现场会议召开时间：2025 年 9 月 10 日（星期三）15:00； （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 9 月 10 日的交易时间，即 9:15 - 9:25，9:30 - 11:30 和 13:00 - 15:00；通 过深圳证券交易所互联网投票系统（http://wltp.cninfo.com.cn）投票的具体时间 为：2025 年 9 月 10 日 9:15 - 15:00。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 2、现场会议召开地点：长沙市雨花区万家丽中路一段 426 号高桥大健康医 药城 8 楼 801 会议室。 特别提示： 1、本次股东会未出现否决议案的情形。 4、会议召集人：公司董事会 （1）股东出席会议 ...

可孚医疗科技股份有限公司 章 程 （草案） （H 股发行并上市后适用） 2025年9月 1 | 第一章 | 总则 | 3 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 4 | | 第三章 | 股份 | 5 | | 第一节 | 股份发行 | 5 | | 第二节 | 股份增减和回购 | 7 | | 第三节 | 股份转让 | 8 | | 第四章 | 股东和股东会 | 9 | | 第一节 | 股东 | 9 | | 第二节 | 控股股东和实际控制人 | 12 | | 第三节 | 股东会的一般规定 | 14 | | 第四节 | 股东会的召集 | 18 | | 第五节 | 股东会的提案与通知 | 19 | | 第六节 | 股东会的召开 | 21 | | 第七节 | 股东会的表决和决议 | 24 | | 第五章 | 董事和董事会 | 28 | | 第一节 | 董事 | 28 | | 第二节 | 董事会 | 32 | | 第三节 | 独立董事 | 37 | | 第四节 | 董事会专门委员会 | 40 | | 第六章 | 总裁及其他高级管理人员 | 42 | | 第七章 | 财务会计制度、利润分 ...

Group 1 - The company, KeFu Medical (301087), expressed an open attitude towards collaborating with outstanding domestic enterprises to promote the development and application of AI medical technology [1] - As of now, the company has not established a direct cooperation relationship with Huawei in the field of AI medical technology [1]

Core Viewpoint - The recent trend of companies from Changsha, including Junxin Co. and Kefu Medical, applying for H-share listings on the Hong Kong Stock Exchange reflects a strategic move towards internationalization and enhanced financing capabilities following the successful listing of Lens Technology [1][2][12] Group 1: Company Listings - Junxin Co. submitted its application for H-share listing on August 13, aiming to become the first "A+H" environmental private company in China if successful [2][6] - Kefu Medical submitted its application on August 29, with plans to use the raised funds for global expansion, R&D innovation, domestic sales channel development, brand promotion, and operational reserves [4][6] Group 2: Industry Context - The "A+H" listing model has precedents in Changsha, with companies like Zoomlion and Lens Technology already adopting this strategy, indicating a growing trend among local firms [7] - Both Junxin Co. and Kefu Medical are recognized leaders in their respective industries, with Junxin Co. being a key player in solid waste management and Kefu Medical being a top home medical device company in China [8][9] Group 3: Strategic Implications - The move to list on the Hong Kong Stock Exchange is seen as a way to enhance global competitiveness and reduce reliance on a single market, providing long-term funding support for technological upgrades and global expansion [11][12] - The successful listing is expected to improve brand visibility and credibility in international markets, facilitating partnerships with global clients and aiding in the exploration of new markets [11][12]

Core Viewpoint - The company has not established a direct partnership with Huawei in the AI medical field, despite its openness to collaboration with leading domestic enterprises to promote the development and application of AI medical technology [1]. Company Summary - The company, KeFu Medical (301087.SZ), expressed its willingness to collaborate with outstanding domestic companies to advance AI medical technology [1]. - As of now, there is no direct cooperation between the company and Huawei in the AI medical sector [1].

Group 1 - The company, Kefo Medical, announced an investment in Newlink Medical, focusing on implantable brain-machine interface technology to develop bionic eyes and ears [1] - This investment is expected to create strategic synergy with the company's existing hearing business, particularly in addressing congenital hearing loss [1]